LBA1 Unraveling the mechanism of action and resistance to trastuzumab deruxtecan (T-DXd): Biomarker analyses from patients from DAISY trial
M.F. Mosele, Amélie Lusque, Véronique Dièras, Élise Deluche, Agnès Ducoulombier, Barbara Pistilli, T. Bachelot, F. Viret, Christelle Lévy, Nicolas Signolle, D. Tran, Ingrid Garberis, Loic Le-Bescond, Alicia Tran Dien, Nathalie Droin, Michihiko Kobayashi, Tomoya Kakegawa, Martha Jimenez, Magali Lacroix‐Triki, Fabrice André
Topics & Concepts
MedicineTremelimumabImmunohistochemistryAntibodyOncologyInternal medicineTrastuzumabBiomarkerNivolumabCancerImmunotherapyIpilimumabBreast cancerImmunologyChemistryBiochemistryHER2/EGFR in Cancer ResearchCancer Immunotherapy and BiomarkersCancer Cells and Metastasis